Ovid Therapeutics Inc. (OVID)Healthcare | Biotechnology | New York, United States | NasdaqCM
2.80 USD
-0.13
(-4.437%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.81 +0.01 (0.357%) ⇧ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:48 a.m. EDT
The investment case for Ovid Therapeutics is severely compromised by a deteriorating business trajectory. The company is reporting a massive contraction in revenue, down nearly 88% year-over-year, and is burning through cash with negative free cash flow. While the balance sheet currently shows a high current ratio due to cash reserves, the operational reality is stark: the company is shrinking rapidly and generating losses. The price action reflects this distress, having lost over 87% of its value over the past eight years, with the last two years seeing double-digit declines. Analyst optimism and penny stock hype cannot mask the fundamental rot; the stock is trading at a premium to sales despite zero earnings and collapsing top-line growth. For the short term, the lack of a clear catalyst and the heavy put positioning suggest a lack of immediate upward momentum, making it a neutral-to-bearish play until the revenue story turns around. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.059923 |
| MSTL | 0.070494 |
| AutoARIMA | 0.071110 |
| AutoETS | 0.071111 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.00 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.308 |
| Excess Kurtosis | -1.11 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.058 |
| Revenue per Share | 0.013 |
| Market Cap | 546,833,984 |
| Forward P/E | -7.10 |
| Beta | 0.23 |
| Website | https://www.ovidrx.com |
As of Aug. 22, 2026, 4:48 a.m. EDT: Speculators are heavily positioned for downside protection with significant open interest in out-of-the-money puts at strikes well below the current price, while call activity is concentrated in deep out-of-the-money strikes far above current levels. This asymmetry suggests a market expectation of continued volatility or further decline rather than an imminent rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3821139 |
| Address1 | Hudson Commons |
| Address2 | 441 9th Avenue 14th Floor |
| All Time High | 15.929 |
| All Time Low | 0.243 |
| Ask | 2.82 |
| Ask Size | 1 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,582,220 |
| Average Daily Volume3 Month | 2,311,875 |
| Average Volume | 2,311,875 |
| Average Volume10Days | 1,582,220 |
| Beta | 0.227 |
| Bid | 2.8 |
| Bid Size | 2 |
| Book Value | 1.136 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.8 |
| Current Ratio | 12.386 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.93 |
| Day Low | 2.76 |
| Debt To Equity | 6.058 |
| Display Name | Ovid Therapeutics |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,400,200 |
| Earnings Timestamp Start | 1,794,400,200 |
| Ebitda | -57,974,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -7.63 |
| Enterprise To Revenue | 279.425 |
| Enterprise Value | 442,329,984 |
| Eps Current Year | -0.38333 |
| Eps Forward | -0.39429 |
| Eps Trailing Twelve Months | -0.2 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 646 661 4027 |
| Fifty Day Average | 2.5675 |
| Fifty Day Average Change | 0.23249984 |
| Fifty Day Average Change Percent | 0.090554945 |
| Fifty Two Week Change Percent | 138.2114 |
| Fifty Two Week High | 3.105 |
| Fifty Two Week High Change | -0.30500007 |
| Fifty Two Week High Change Percent | -0.098228686 |
| Fifty Two Week Low | 1.12 |
| Fifty Two Week Low Change | 1.68 |
| Fifty Two Week Low Change Percent | 1.5 |
| Fifty Two Week Range | 1.12 - 3.105 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,493,991,000,000 |
| Float Shares | 163,388,140 |
| Forward Eps | -0.39429 |
| Forward P E | -7.101372 |
| Free Cashflow | -33,121,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 23 |
| Fullday Change | -0.13 |
| Fullday Change Percent | -4.43686 |
| Fullday Price | 2.81 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,583,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06724 |
| Held Percent Institutions | 0.80331004 |
| Implied Shares Outstanding | 195,297,857 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. |
| Long Name | Ovid Therapeutics Inc. |
| Market | us_market |
| Market Cap | 546,833,984 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_288870432 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -34,477,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 572,222,721 |
| Number Of Analyst Opinions | 9 |
| Open | 2.87 |
| Operating Cashflow | -54,773,000 |
| Operating Margins | -21.006819 |
| Payout Ratio | 0.0 |
| Phone | 646 661 7661 |
| Post Market Change | 0.00999999 |
| Post Market Change Percent | 0.3571425 |
| Post Market Price | 2.81 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 2.93 |
| Price Eps Current Year | -7.3044114 |
| Price Hint | 4 |
| Price To Book | 2.4647887 |
| Price To Sales Trailing12 Months | 345.44156 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.745 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.13 |
| Regular Market Change Percent | -4.43686 |
| Regular Market Day High | 2.93 |
| Regular Market Day Low | 2.76 |
| Regular Market Day Range | 2.76 - 2.93 |
| Regular Market Open | 2.87 |
| Regular Market Previous Close | 2.93 |
| Regular Market Price | 2.8 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,673,730 |
| Return On Assets | -0.23456 |
| Return On Equity | -0.25964 |
| Revenue Growth | -0.883 |
| Revenue Per Share | 0.013 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 195,297,857 |
| Shares Percent Shares Out | 0.1108 |
| Shares Short | 21,636,407 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 22,039,852 |
| Short Name | Ovid Therapeutics Inc. |
| Short Percent Of Float | 0.1269 |
| Short Ratio | 14.69 |
| Source Interval | 15 |
| State | NY |
| Symbol | OVID |
| Target High Price | 9.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 5.69333 |
| Target Median Price | 5.0 |
| Total Cash | 117,219,000 |
| Total Cash Per Share | 0.6 |
| Total Debt | 12,715,000 |
| Total Revenue | 1,583,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.2 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.1524 |
| Two Hundred Day Average Change | 0.64759994 |
| Two Hundred Day Average Change Percent | 0.3008734 |
| Type Disp | Equity |
| Volume | 1,673,730 |
| Website | https://www.ovidrx.com |
| Zip | 10,001 |